Estrogen receptors are the primary regulators of gene function in female reproductive tissues. They do so by recruiting a series of 'coregulators'(coactivators to activate genes, or corepressors to repress genes). Most coregulators are enzymes and many of them are recruited simultaneously to form large complexes bound to a receptor at a given target gene. We know a great deal about the production of the hormone (estrogen) and a good deal about the estrogen receptor. However, much less is known about the complement of coactivators that bind to receptor at a specific target gene. For instance, what specific relative roles the DNA sequence, the posttranslational modifications of the associated proteins, and the compositions of histones play in activating its target gene. We feel we can best contribute specific new information to these questions by studying direct formation of the 'active receptor-coactivator'complexes in vitro, under conditions where we can control the compositions and posttranslational modifications of the components in the complex - all under conditions where we can monitor the final outcome activation of transcriptional expression of the gene into messenger RNA. We plan to approach these questions using biochemical, physical structural and cell-based methodologies. We have developed within the project a means (Cryo-EM) to 'directly visualize'and model the receptor-coactivator complexes that we form in vitro. When we define the DNA bound receptor- complex of coactivators and the histone marks, we then use this information to understand the roles of these molecular reactions in disease states such as reproductive tissue inflammatory diseases and reproductive tissue cancers. When we determine a critical coactivator or histone mark that allows a disease process gene to function aberrantly, we next search for small molecule drugs that will inhibit/activate this molecular targe to favor therapy for the pathology in question. When the cell-free and whole cell studies indicate therapeutic possibilities for a new drug for a disease (e.g., breast cancer), we then test the drug in standard animal models. In preliminary studies described in our grant proposal, we demonstrate this roadmap to therapy can be used successfully to uncover new therapeutic drugs for given diseases of reproductive and oncogenic tissues.
The project has great relevance to diseases of female reproductive tissues. Uncovering the mechanism of how a disease occurs is the best approach to insightful design of new drug targets and therapies. Our project is focused primarily on understanding disease causes so as to discover new therapies for major afflictions of women such as endometriosis and breast cancer.
|Feng, Qin; Zhang, Zheng; Shea, Martin J et al. (2014) An epigenomic approach to therapy for tamoxifen-resistant breast cancer. Cell Res 24:809-19|
|Motamed, Massoud; Rajapakshe, Kimal I; Hartig, Sean M et al. (2014) Steroid receptor coactivator 1 is an integrator of glucose and NAD+/NADH homeostasis. Mol Endocrinol 28:395-405|
|Wang, Ying; Lonard, David M; Yu, Yang et al. (2014) Bufalin is a potent small-molecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1. Cancer Res 74:1506-17|
|Wang, Wei; Bian, Ka; Vallabhaneni, Sreeram et al. (2014) ERK3 promotes endothelial cell functions by upregulating SRC-3/SP1-mediated VEGFR2 expression. J Cell Physiol 229:1529-37|
|Stashi, Erin; York, Brian; O'Malley, Bert W (2014) Steroid receptor coactivators: servants and masters for control of systems metabolism. Trends Endocrinol Metab 25:337-47|
|York, Brian; Sagen, Jørn V; Tsimelzon, Anna et al. (2013) Research resource: tissue- and pathway-specific metabolomic profiles of the steroid receptor coactivator (SRC) family. Mol Endocrinol 27:366-80|
|Foulds, Charles E; Feng, Qin; Ding, Chen et al. (2013) Proteomic analysis of coregulators bound to ER* on DNA and nucleosomes reveals coregulator dynamics. Mol Cell 51:185-99|
|Long, Weiwen; Foulds, Charles E; Qin, Jun et al. (2012) ERK3 signals through SRC-3 coactivator to promote human lung cancer cell invasion. J Clin Invest 122:1869-80|
|Johnson, Amber B; O'Malley, Bert W (2012) Steroid receptor coactivators 1, 2, and 3: critical regulators of nuclear receptor activity and steroid receptor modulator (SRM)-based cancer therapy. Mol Cell Endocrinol 348:430-9|
|Reddy, Sirigiri Divijendra Natha; Rayala, Suresh K; Ohshiro, Kazufumi et al. (2011) Multiple coregulatory control of tyrosine hydroxylase gene transcription. Proc Natl Acad Sci U S A 108:4200-5|
Showing the most recent 10 out of 25 publications